USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...
Conference Call and Webcast Scheduled for Wednesday, July 30
SAN DIEGO, July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it...
Celebrating the bold leaders shaping the future through the world's most ground-breaking companies
WEST VALLEY, Utah, July 9, 2025 /PRNewswire/ -- Ernst & Young LLP...
STRASBOURG, France, July 9, 2025 /PRNewswire/ -- The International Human Frontier Science Program Organization (HFSPO) is pleased to award the 2026 HFSP Nakasone Award...
NEW HAVEN, Conn., July 8, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) was awarded a $27.7 million grant from Aligning Research...
TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent exposure. This study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, which is investigating pharmacological compounds, including Bucillamine, capable of mitigating nerve agent-induced brain injury.
MIAMI, July 8, 2025 /PRNewswire/ -- Struggling to start a workout routine or stick with one? New research offers a surprising insight: your brain, not...
ELNORA, Ind., July 8, 2025 /PRNewswire/ -- Skylark Labs has secured multiple contracts to deploy its Scout Towers along Indiana's busiest highways, providing the...
In this 2025 ingredient transparency update, Emma highlights growing public interest in methane-producing gut bacteria, microbiome imbalance, and non-clinical digestive support. The release explores how plant-based formulations may help support intestinal motility, microbial balance, and daily bowel regularity without relying on probiotics or synthetic cleanses.
In this 2025 ingredient transparency update, Emma highlights growing public interest in methane-producing gut bacteria, microbiome imbalance, and non-clinical digestive support. The release explores how plant-based formulations may help support intestinal motility, microbial balance, and daily bowel regularity without relying on probiotics or synthetic cleanses.
Clean-label hydration meets real-world functionality in NativePath’s new stick pack assortment featuring natural flavors, third-party tested ingredients, and a complete hydration matrix designed for daily wellness.
Clean-label hydration meets real-world functionality in NativePath’s new stick pack assortment featuring natural flavors, third-party tested ingredients, and a complete hydration matrix designed for daily wellness.
NativePath’s Clean-Label Creatine Powder Combines L-Leucine, L-Carnitine, and Creatine Monohydrate for Daily Muscle and Energy Support Without Resistance Training
NativePath’s Clean-Label Creatine Powder Combines L-Leucine, L-Carnitine, and Creatine Monohydrate for Daily Muscle and Energy Support Without Resistance Training
Validation Data on 60 Patients published in Cancer Genetics
CHICAGO, July 7, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development...